GlaxoSmithKline Pharmaceuticals · NSE: GLAXO · BSE: 500660
Q2 FY21 results · Jul–Sep 2020
GlaxoSmithKline Pharmaceuticals reported revenue from operations of ₹879.32 crore (down 0.3% from Q2 FY20) and net profit of ₹76.47 crore (down 84.8% from Q2 FY20) for Q2 FY21 (Jul–Sep 2020), on a consolidated basis.
| Item | Q2 FY21 | Q2 FY20 | YoY | Q1 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 879.32 | 882.02 | −0.3% | 648.59 | +35.6% |
| Other income | 9.04 | 15.88 | −43.1% | 57.92 | −84.4% |
| Total income | 888.36 | 897.90 | −1.1% | 706.51 | +25.7% |
| Profit before tax | 126.93 | 587.41 | −78.4% | 149.14 | −14.9% |
| Net profit for the period | 76.47 | 502.75 | −84.8% | 110.83 | −31.0% |
| EPS, basic (₹) | 4.51 | 29.68 | −84.8% | 6.54 | −31.0% |
| Net margin (%) | 8.7 | 57.0 | 17.1 |
| Item | Q2 FY21 | Q2 FY20 | YoY | Q1 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 879.39 | 882.10 | −0.3% | 648.65 | +35.6% |
| Other income | 8.92 | 15.61 | −42.9% | 57.79 | −84.6% |
| Total income | 888.31 | 897.71 | −1.0% | 706.44 | +25.7% |
| Profit before tax | 126.97 | 587.37 | −78.4% | 149.29 | −15.0% |
| Net profit for the period | 76.50 | 502.79 | −84.8% | 110.96 | −31.1% |
| EPS, basic (₹) | 4.52 | 29.68 | −84.8% | 6.55 | −31.0% |
| Net margin (%) | 8.7 | 57.0 | 17.1 |
Consolidated
- Filed with BSE
- 29 Oct 2020, 19:22 IST
- Board meeting
- 28 Oct 2020
- Period
- 01 Jul 2020 to 30 Sep 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 29 Oct 2020, 19:22 IST
- Board meeting
- 28 Oct 2020
- Period
- 01 Jul 2020 to 30 Sep 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE